Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient

Maile Young Karris

doi:10.1089/aid.2016.0180

Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient

AIDS Research and Human Retroviruses ◽

10.1089/aid.2016.0180 ◽

2017 ◽

Vol 33 (7) ◽

pp. 718-722 ◽

Cited By ~ 9

Author(s):

Maile Young Karris

Keyword(s):

Hepatitis B ◽

Tenofovir Disoproxil Fumarate ◽

Fanconi Syndrome ◽

Short Communication ◽

Tenofovir Alafenamide ◽

Coinfected Patient ◽

Hiv 1

Download Full-text

Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV‐1‐infected patients: a real‐world study in Japan

HIV Medicine ◽

10.1111/hiv.13061 ◽

2021 ◽

Author(s):

Naoki Kanda ◽

Koh Okamoto ◽

Hisatoshi Okumura ◽

Makiko Mieno ◽

Kentaro Sakashita ◽

...

Keyword(s):

Real World ◽

Tenofovir Disoproxil Fumarate ◽

Treatment Change ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text

Longer-Term Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide Versus Emtricitabine and Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Week 96 Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3772801 ◽

2021 ◽

Author(s):

Onyema Ogbuagu ◽

Peter J. Ruane ◽

Daniel Podzamczer ◽

Laura C. Salazar ◽

Keith Henry ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Tenofovir Alafenamide ◽

Exposure Prophylaxis ◽

Hiv 1

Download Full-text

IDDF2018-ABS-0108 Improved bone and renal safety at 1 year after switching from TENOFOVIR DISOPROXIL FUMARATE (TDF) to TENOFOVIR ALAFENAMIDE (TAF): results from 2 phase 3 studies in HBEAG-positive and HBEAG-negative patients with chronic hepatitis B (CHB)

10.1136/gutjnl-2018-iddfabstracts.209 ◽

2018 ◽

Cited By ~ 1

Author(s):

Henry Lek-Yuen Chan ◽

Calvin Pan ◽

Maurizia Brunetto ◽

Aric Josun Hui ◽

Rajiv Mehta ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Tenofovir Disoproxil Fumarate ◽

Phase 3 ◽

Tenofovir Alafenamide ◽

Renal Safety

Download Full-text

Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide

Journal of Viral Hepatitis ◽

10.1111/jvh.13053 ◽

2019 ◽

Vol 26 (5) ◽

pp. 561-567 ◽

Cited By ~ 9

Author(s):

Tse‐Ling Fong ◽

Brian T. Lee ◽

Andy Tien ◽

Mimi Chang ◽

Carolina Lim ◽

...

Keyword(s):

Bone Mineral Density ◽

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Bone Mineral ◽

Tenofovir Disoproxil Fumarate ◽

Mineral Density ◽

Renal Tubular Function ◽

Tenofovir Alafenamide ◽

Renal Tubular

Download Full-text

IDDF2019-ABS-0169 A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results

10.1136/gutjnl-2019-iddfabstracts.278 ◽

2019 ◽

Author(s):

Henry Lik Yuen Chan ◽

Pietro Lampertico ◽

Maria Buti ◽

Scott Fung ◽

Sang Hoon Ahn ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Tenofovir Disoproxil Fumarate ◽

Efficacy And Safety ◽

Phase 3 ◽

Tenofovir Alafenamide

Download Full-text

Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

The Lancet HIV ◽

10.1016/s2352-3018(17)30032-2 ◽

2017 ◽

Vol 4 (5) ◽

pp. e205-e213 ◽

Cited By ~ 30

Author(s):

Edwin DeJesus ◽

Moti Ramgopal ◽

Gordon Crofoot ◽

Peter Ruane ◽

Anthony LaMarca ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Double Blind ◽

Multicentre Phase ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(15)00348-5 ◽

2016 ◽

Vol 16 (1) ◽

pp. 43-52 ◽

Cited By ~ 155

Author(s):

Anthony Mills ◽

Jose R Arribas ◽

Jaime Andrade-Villanueva ◽

Giovanni DiPerri ◽

Jan Van Lunzen ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text

Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Negative, Chronic Hepatitis B Patients: A Global Phase 3 Study

Gastroenterology ◽

10.1016/s0016-5085(17)33661-2 ◽

2017 ◽

Vol 152 (5) ◽

pp. S1086

Author(s):

Maurizia Rossana Brunetto ◽

Young-Suk Lim ◽

Edward Gane ◽

Wai-Kay Seto ◽

Marina Osipenko ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Tenofovir Disoproxil Fumarate ◽

Efficacy And Safety ◽

Phase 3 ◽

Tenofovir Alafenamide ◽

Negative Chronic Hepatitis

Download Full-text

Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Positive Patients: A Global Phase 3 Study

Gastroenterology ◽

10.1016/s0016-5085(17)33660-0 ◽

2017 ◽

Vol 152 (5) ◽

pp. S1085-S1086

Author(s):

Kosh Agarwal ◽

Scott Fung ◽

Wai-Kay Seto ◽

Young-Suk Lim ◽

Edward Gane ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Tenofovir Disoproxil Fumarate ◽

Efficacy And Safety ◽

Phase 3 ◽

Tenofovir Alafenamide

Download Full-text

Switching from a Tenofovir Disoproxil Fumarate (TDF) to a Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen (STR): Week 48 Data in HIV-1-Infected Virologically Suppressed Adults

Open Forum Infectious Diseases ◽

10.1093/ofid/ofv131.78 ◽

2015 ◽

Vol 2 (suppl_1) ◽

Author(s):

Melanie Thompson ◽

Javier Morales-Ramirez ◽

Cheryl Mcdonald ◽

Anita Rachlis ◽

Christian Hoffmann ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Single Tablet Regimen ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text